Table 2.
Adverse events
| Ofatumumab | Rituximab | P value | |
|---|---|---|---|
| (n=70), n (%) | (n=70), n (%) | ||
| Adverse events infusion related | |||
| SAEs (Grade ≥3) | 0 | 0 | 1.00 |
| Not SAEs (Grade <3) | 4 (6) | 7 (10) | 0.34 |
| Pruritus | 1 (1) | 3 (4) | 0.37 |
| Erythema | 2 (3) | 2 (3) | 1.00 |
| Glottis edema | 0 | 0 | 1.00 |
| Dyspnea | 0 | 1 (1) | 0.68 |
| Fever | 0 | 0 | 1.00 |
| Cough | 1 (1) | 1 (1) | 1.00 |
| Adverse events within 6 months | |||
| SAEs (Grade ≥3) | 0 | 0 | 1.00 |
| Not SAEs (Grade <3) | 1 (1) | 4 (6) | 0.31 |
| Neutropenia | 1 (1) | 2 (3) | 0.68 |
| Duration, days | 20 | 30/50 | |
| Articular pain | 0 | 2 (3) | 0.58 |
| Duration, days | 3 | ||
| Therapy | paracetamol |
Adverse events were reported on the basis of the time of their occurrence and on clinical severity. Articular pain is due to the chimeric structure of rituximab and mimics a serum sickness effect. SAEs, serious adverse events.